10 tuloksia
CROSS REFERENCE TO RELATED APPLICATION
This application is a 371 of PCT/JP05/022367, filed on Dec. 6, 2005, and claims priority to Japanese Patent Application No. 2004-353725, filed on Dec. 7, 2004.
TECHNICAL FIELD
The present invention relates to a novel anthranilic acid derivative or a salt
The invention relates to new anthranilic acid amide derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof--alone or in combination with one or more other pharmaceutically active compounds--for the
The invention relates to new anthranilic acid amide derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof--alone or in combination with one or more other pharmaceutically active compounds--for the
This application is a 35 U.S.C. .sctn. 371 national phase entry application of PCT/GB97/02885 filed Oct. 17, 1997.
The present invention relates to compounds useful as modulators of multi-drug resistance (MDR), in particular MDR caused by over-production of P-glycoprotein (P-gp), to their
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a method for determining whether or not a mammal is affected with a lung cancer.
2. Description of the Related Art
Substances (a kind of proteins) that exist in a large amount only in cancer cells but either do
The invention relates to new anthranilic acid amide derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof--alone or in combination with one or more other pharmaceutically active compounds--for the
FIELD OF THE INVENTION
The present invention relates to novel anthranilic acid derivatives, which are stable towards oxidation by human cytochrome P450 and are potent inhibitors of dihydroorotate dehydrogenase (DHODH), to be used for clinical treatment of autoimmune diseases, inflammatory diseases,
FIELD OF THE INVENTION
The present invention relates to novel anthranilic acid derivatives, which are stable towards oxidation by human cytochrome P450 and are potent inhibitors of dihydroorotate dehydrogenase (DHODH), to be used for clinical treatment of autoimmune diseases, inflammatory diseases,
CROSS REFERENCE TO RELATED APPLICATIONS
The present application is a .sctn. 371 National Phase application based on PCT/IB2015/057254 filed Sep. 21, 2015, which claims the benefit of Application Nos. 3148/MUM/2014, filed Oct. 3, 2014 and 3588/MUM/2014, filed Nov. 13, 2014, the subject matter of each
The invention relates to new benzamide derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof--alone or in combination with one or more other pharmaceutically active compounds--for the treatment